Erythropoietin and the vascular wall: Thecontroversy continues

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue SUPPL1, 2013, Pages

  Jelkmann, W ^a   Elliott, S ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b AMGEN INC   (United States)

Author keywords

Angiogenesis; Endothelial cells; Erythropoietin receptor; Heart failure; Myocardial infarct

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; BLOOD CLOTTING; BLOOD PRESSURE; BLOOD VESSEL WALL; ERYTHROPOIESIS; HEART; HEART FAILURE; HEART INFARCTION; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL FACTOR; TISSUE OXYGENATION; VENOUS THROMBOEMBOLISM; WESTERN BLOTTING;

ANGIOGENESIS; ENDOTHELIAL CELLS; ERYTHROPOIETIN RECEPTOR; HEART FAILURE; MYOCARDIAL INFARCT;

ANIMALS; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, ERYTHROPOIETIN;

EID: 84890863187     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.04.002     Document Type: Review

References (59)

1. Sawada K., Krantz S.B., Sawyer S.T., Civin C.I. Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells. J Cell Physiol 1988, 137:337-345.
2. Broudy V.C., Lin N., Brice M., Nakamoto B., Papayannopoulou T. Erythropoietin receptor characteristics on primary human erythroid cells. Blood 1991, 77:2583-2590.
3. Noguchi C.T., Bae K.S., Chin K., Wada Y., Schechter A.N., Hankins W.D. Cloning of the human erythropoietin receptor gene. Blood 1991, 78:2548-2556.
4. Jelkmann W., Bohlius J., Hallek M., Sytkowski A.J. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008, 67:39-61.
5. Sinclair A.M., Todd M.D., Forsythe K., Knox S.J., Elliott S., Begley C.G. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007, 110:477-488.
6. Jelkmann W., Depping R., Metzen E. Nonhematopoietic effects of erythropoiesis-stimulating agents. Erythropoietins, erythropoietic factors, and erythropoiesis 2009, 299-317. Birkhäuser. S.G. Elliott, M.-A. Foote, G. Molineux (Eds.).
7. Suzuki N., Ohneda O., Takahashi S., Higuchi M., Mukai H.Y., Nakahata T., et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002, 100:2279-2288.
8. D'Andrea A.D., Lodish H.F., Wong G.G. Expression cloning of the murine erythropoietin receptor. Cell 1989, 57:277-285.
9. Sinclair A.M., Coxon A., McCaffery I., Kaufman S., Paweletz K., Liu L., et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 2010, 115:4264-4272.
10. Elliott S, Busse L, Swift S, McCaffery I, Rossi J, Kassner P, etal. Lack of expression and function of erythropoietin receptors in the kidney. Nephrol Dial Transplant 201; Dec 13. [Epub ahead of print].
11. Sawyer S.T., Krantz S.B., Goldwasser E. Binding and receptor-mediated endocytosis of erythropoietin in friend virus-infected erythroid cells. J Biol Chem 1987, 262:5554-5562.
12. Elliott S., Sinclair A.M., Begley C.G. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006, 107:1892-1895.
13. Kirkeby A., van B.J., Nielsen J., Leist M., Helboe L. Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor. J Neurosci Methods 2007, 164:50-58.
14. Laugsch M., Metzen E., Svensson T., Depping R., Jelkmann W. Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 2008, 122:1005-1011.
15. Elliott S., Busse L., McCaffery I., Rossi J., Sinclair A., Spahr C., et al. Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J Immunol Methods 2010, 352:126-139.
16. Wu H., Lee S.H., Gao J., Liu X., Iruela-Arispe M.L. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999, 126:3597-3605.
17. Yu X., Shacka J.J., Eells J.B., Suarez-Quian C., Przygodzki R.M., Beleslin-Cokic B., et al. Erythropoietin receptor signalling is required for normal brain development. Development 2002, 129:505-516.
18. Teng R., Gavrilova O., Suzuki N., Chanturiya T., Schimel D., Hugendubler L., et al. Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. Nat Commun 2011, 2:520. 10.1038/ncomms1526.
19. Westenbrink B.D., Ruifrok W.P., Voors A.A., Tilton R.G., van Veldhuisen D.J., Schoemaker R.G., et al. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. Cardiovasc Res 2010, 87:30-39.
20. Broberg A.M., Grinnemo K.H., Genead R., Danielsson C., Andersson A.B., Wardell E., et al. Erythropoietin has an antiapoptotic effect after myocardial infarction and stimulates invitro aortic ring sprouting. Biochem Biophys Res Commun 2008, 371:75-78.
21. Fiordaliso F., Chimenti S., Staszewsky L., Bai A., Carlo E., Cuccovillo I., et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 2005, 102:2046-2051.
22. Scott C.L., Robb L., Papaevangeliou B., Mansfield R., Nicola N.A., Begley C.G. Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor. Blood 2000, 96:1588-1590.
23. Liem A., van de Woestijne A.P., Bruijns E., Roeters van Lennep H.W., de Boo J.A., van Halteren H.K., et al. Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol 2009, 131:285-287.
24. Ozawa T., Toba K., Suzuki H., Kato K., Iso Y., Akutsu Y., et al. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI -1 study. Circ J 2010, 74:1415-1423.
25. Taniguchi N., Nakamura T., Sawada T., Matsubara K., Furukawa K., Hadase M., et al. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J 2010, 74:2365-2371.
26. Ludman A.J., Yellon D.M., Hasleton J., Ariti C., Babu G.G., Boston-Griffiths E., et al. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart 2011, 97:1560-1565.
27. Ott I., Schulz S., Mehilli J., Fichtner S., Hadamitzky M., Hoppe K., et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 2010, 3:408-413.
28. Voors A.A., Belonje A.M., Zijlstra F., Hillege H.L., Anker S.D., Slart R.H., et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010, 31:2593-2600.
29. Najjar S.S., Rao S.V., Melloni C., Raman S.V., Povsic T.J., Melton L., et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011, 305:1863-1872.
30. van der Meer P., Groenveld H.F., Januzzi J.L., van Veldhuisen D.J. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009, 95:1309-1314.
31. Locatelli F., Gascon P. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? treatment guidelines and an update on benefits and risks. Oncologist 2009, 14:57-62.
32. Abraham W.T., Anand I.S., Klapholz M., Ponikowski P., Scarlata D., Wasserman S.M., et al. Treatment of anemia with darbepoetin alfa in heart failure. Congest Heart Fail 2010, 16:87-95.
33. Fraser J.K., Lin F.K., Berridge M.V. Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line, HEL. Exp Hematol 1988, 16:836-842.
34. Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
35. Pfeffer M.A., Burdmann E.A., Chen C.Y., Cooper M.E., de Zeeuw D., Eckardt K.U., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361:2019-2032.
36. Ehrenreich H., Weissenborn K., Prange H., Schneider D., Weimar C., Wartenberg K., et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009, 40:e656-656.
37. Tojo A., Doumoto M., Oka K., Numabe A., Kimura K., Yagi S. Endothelin-mediated effect of erythropoietin on blood pressure and renal hemodynamics in hypertensive rats. Am J Phys 1996, 270:R744-R748.
38. Abiose A.K., Aronow W.S., Moreno H., Nair C.K., Blaschke T.F., Hoffman B.B. Increased vascular alpha1-adrenergic sensitivity in patients with renal failure: receiving recombinant erythropoeitin. Am J Ther 2007, 14:427-434.
39. Anagnostou A., Lee E.S., Kessimian N., Levinson R., Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990, 87:5978-5982.
40. Anagnostou A., Liu Z., Steiner M., Chin K., Lee E.S., Kessimian N., et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994, 91:3974-3978.
41. Yamaji R., Okada T., Moriya M., Naito M., Tsuruo T., Miyatake K., et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 1996, 239:494-500.
42. Fuste B., Serradell M., Escolar G., Cases A., Mazzara R., Castillo R., et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices invitro. Thromb Haemost 2002, 88:678-685.
43. Fodinger M., Fritsche-Polanz R., Buchmayer H., Skoupy S., Sengoelge G., Hörl W.H., et al. Erythropoietin-inducible immediate-early genes in human vascular endothelial cells. J Investig Med 2000, 48:137-149.
44. Jaquet K., Krause K., Tawakol-Khodai M., Geidel S., Kuck K.H. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002, 64:326-333.
45. Lopez Ongil S.L., Saura M., Lamas S., Rodriguez P.M., Rodriguez P.D. Recombinant human erythropoietin does not regulate the expression of endothelin-1 and constitutive nitric oxide synthase in vascular endothelial cells. Exp Nephrol 1996, 4:37-42.
46. Zwezdaryk K.J., Coffelt S.B., Figueroa Y.G., Liu J., Phinney D.G., LaMarca H.L., et al. Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells. Exp Hematol 2007, 35:640-652.
47. Buhring H.J., Muller C.A., Letarte M., Gougos A., Saalmuller A., van Agthoven A.J., et al. Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia 1991, 5:841-847.
48. Bahlmann F.H., De Groot K., Spandau J.M., Landry A.L., Hertel B., Duckert T., et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004, 103:921-926.
49. Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003, 102:1340-1346.
50. Kim S.N., Moon J.H., Kim J.G., Chae Y.S., Cho Y.Y., Lee S.J., et al. Mobilization effects of G-CSF, GM-CSF, and darbepoetin-alpha for allogeneic peripheral blood stem cell transplantation. J Clin Apheresis 2009, 24:173-179.
51. Pawlak K., Pawlak D., Mysliwiec M. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients. Thromb Res 2007, 120:797-803.
52. Janmaat M.L., Heerkens J.L., de Bruin A.M., Klous A., de Waard V., de Vries C.J. Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release. Blood 2010, 115:1453-1460.
53. Ribatti D. Erythropoietin and tumor angiogenesis. Stem Cells Dev 2010, 19:1-4.
54. Hardee M.E., Kirkpatrick J.P., Shan S., Snyder S.A., Vujaskovic Z., Rabbani Z.N., et al. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer 2005, 93:1350-1355.
55. Sairah A.K., Rasedee A., Sheikh O., Rozita R., Alhaj N. The effects of recombinant human erythropoietin and tomoxifen on growth and angiogenesis of mammary tumor in Sprague-Dawley rat. Am J Pharmacol Toxicol 2009, 4:12-16.
56. Machein M.R., Renninger S., de Lima-Hahn E., Plate K.H. Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol 2003, 13:582-597.
57. Peters B.A., Diaz L.A., Polyak K., Meszler L., Romans K., Guinan E.C., et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005, 11:261-262.
58. Bennett C.L., Silver S.M., Djulbegovic B., Samaras A.T., Blau C.A., Gleason K.J., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008, 299:914-924.
59. Aapro M., Barnadas A., Leonard R.C., Marangolo M., Untch M., Ukarma L., et al. What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?. Eur J Cancer 2009, 45:2984-2991.